ADIPOR1 Antibody

What is ADIPOR1 and why is it significant for metabolic research?

ADIPOR1 (Adiponectin Receptor 1) is a 375 amino acid multipass transmembrane protein that serves as a receptor for adiponectin . Its significance in metabolic research stems from its role in mediating increased fatty acid oxidation and glucose uptake stimulated by adiponectin . ADIPOR1 expression in adipose tissue is decreased in obese humans and increases with weight loss, making it a critical target for research into obesity, diabetes, and metabolic syndrome . The protein's role in energy homeostasis positions it as an important therapeutic target for metabolic disorders, which is why antibodies against ADIPOR1 are valuable tools for investigating these conditions.

What applications are ADIPOR1 antibodies suitable for?

ADIPOR1 antibodies are validated for multiple research applications:

These applications allow researchers to detect ADIPOR1 protein expression in various experimental contexts, from tissue sections to cell cultures and protein lysates.

How should ADIPOR1 antibodies be stored to maintain optimal activity?

For long-term storage, ADIPOR1 antibodies should be stored at -20°C . It's important to note that storage in frost-free freezers is not recommended as temperature fluctuations can degrade antibody quality . For short-term storage and frequent use, storage at 4°C for up to one month is recommended . Researchers should avoid repeated freeze-thaw cycles as these can significantly reduce antibody activity . If the antibody solution contains a precipitate, microcentrifugation before use is recommended to ensure optimal performance . Antibodies are typically supplied in buffer solutions containing stabilizers like BSA (0.1%) and preservatives like sodium azide (0.1%) .

How do I select the most appropriate ADIPOR1 antibody for my specific research application?

Selecting the appropriate ADIPOR1 antibody depends on several factors:

• Target species compatibility: Ensure the antibody is validated for your species of interest. Some antibodies react with human, mouse, rat, and zebrafish ADIPOR1 , while others may have more limited species reactivity .

• Application-specific validation: Choose antibodies that have been specifically validated for your application (WB, IHC, IF, etc.). For example, goat polyclonal antibodies might be recommended for IHC-P , while rabbit polyclonal antibodies may offer broader application potential .

• Epitope considerations: Consider which region of ADIPOR1 your research focuses on. Some antibodies recognize epitopes within the N-terminal region , which may be particularly important if you're studying structural variants or protein interactions.

• Clonality requirements: Polyclonal antibodies offer broader epitope recognition but potentially more background, while monoclonal antibodies provide higher specificity for a single epitope .

• Cross-reactivity assessment: Verify that the antibody does not cross-react with other proteins, especially ADIPOR2, which shares structural similarities with ADIPOR1 .

After selection, optimize dilutions for your specific experimental conditions, starting with the manufacturer's recommended range.

What controls should be included when using ADIPOR1 antibodies for immunostaining experiments?

Robust experimental design for ADIPOR1 immunostaining should include:

• Positive tissue controls: Human skeletal muscle or placenta tissues, which naturally express high levels of ADIPOR1 . Heart tissue is also appropriate as ADIPOR1 is highly expressed there .

• Negative controls:

  • Primary antibody omission control

  • Isotype control using non-specific IgG from the same host species

  • Tissue known to lack ADIPOR1 expression

• Blocking peptide controls: Using the immunizing peptide (SSHKGSVVAQGNGAPASNREADTVE) to compete with antibody binding can confirm specificity.

• Cell line controls:

  • Positive: HEK293 cells transfected with human ADIPOR1

  • Negative: Non-transfected cells or cells transfected with irrelevant constructs

• Knockdown/knockout validation: Comparing staining in ADIPOR1 knockdown/knockout samples versus wild-type can definitively validate antibody specificity.

Documentation of these controls is essential for publication-quality research and ensures the reliability of your ADIPOR1 detection methods.

What are the optimal fixation and antigen retrieval methods for ADIPOR1 immunohistochemistry?

For optimal ADIPOR1 detection in immunohistochemistry, consider these methodological recommendations:

• Fixation protocols:

  • Formalin-fixed, paraffin-embedded (FFPE) tissues work well with many ADIPOR1 antibodies

  • For cells, acetone fixation has been reported as suitable for ADIPOR1 detection

  • Paraformaldehyde fixation is appropriate for immunocytochemistry applications

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is generally effective

  • For challenging samples, test alternative pH buffers (e.g., EDTA buffer pH 9.0)

  • Optimal retrieval time should be experimentally determined (typically 10-20 minutes)

• Section thickness:

  • 3-5 μm sections are recommended for paraffin-embedded tissues

• Blocking conditions:

  • Use serum from the species in which the secondary antibody was raised

  • Include 0.1-0.3% Triton X-100 if membrane permeabilization is needed

• Antibody incubation:

  • For IHC-P applications, a dilution of 1:250 is recommended for some goat polyclonal antibodies

  • Others recommend 1:50-1:200 dilution ranges for rabbit polyclonal antibodies

  • Incubation times typically range from 1 hour at room temperature to overnight at 4°C

These parameters should be optimized for each specific tissue type and antibody combination.

How can I address non-specific binding or high background when using ADIPOR1 antibodies?

Non-specific binding and high background are common challenges when working with ADIPOR1 antibodies. To address these issues:

• Antibody dilution optimization:

  • Perform serial dilutions beyond manufacturer recommendations

  • For IHC-P, start with 1:250 and adjust based on signal-to-noise ratio

  • For WB, test dilutions from 1:1000 to 1:5000

• Blocking optimizations:

  • Extend blocking time (1-2 hours at room temperature)

  • Test alternative blocking agents (5% BSA, 5% milk, commercial blockers)

  • Add 0.1-0.3% Triton X-100 for membrane proteins

• Washing modifications:

  • Increase number and duration of washes

  • Add 0.05-0.1% Tween-20 to wash buffers

  • Consider using TBS instead of PBS if phosphate interference is suspected

• Secondary antibody considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Reduce secondary antibody concentration

  • Pre-adsorb secondary against tissue powder from the species being tested

• Tissue-specific treatments:

  • For tissues with high endogenous peroxidase, use 3% H₂O₂ treatment

  • For tissues with high endogenous biotin, use avidin-biotin blocking kit

  • Consider autofluorescence quenching for IF applications

If high background persists, performing peptide competition assays with the immunizing peptide sequence (SSHKGSVVAQGNGAPASNREADTVE) can help differentiate specific from non-specific signals.

What are the best approaches for quantifying ADIPOR1 expression changes in disease models?

Quantifying ADIPOR1 expression changes requires rigorous methodology:

• Western blot quantification:

  • Use internal loading controls (β-actin, GAPDH) for normalization

  • Apply densitometric analysis with appropriate software (ImageJ, Image Studio)

  • Include a standard curve using recombinant ADIPOR1 protein for absolute quantification

  • Perform technical triplicates and biological replicates (n≥3)

• Immunohistochemistry quantification:

  • Use digital pathology software for objective quantification

  • Establish scoring parameters (H-score, percent positive cells, staining intensity)

  • Analyze multiple fields per sample (minimum 5-10 fields)

  • Employ double-blind assessment with multiple observers

• Flow cytometry approaches:

  • Use median fluorescence intensity (MFI) rather than percent positive

  • Include fluorescence minus one (FMO) controls

  • Calculate the specific staining index (SSI) to normalize data

  • Consider multiparameter analysis to correlate with other markers

• RT-qPCR complementation:

  • Combine protein expression data with mRNA quantification

  • Use validated ADIPOR1-specific primers

  • Employ multiple reference genes for normalization

• Statistical analysis requirements:

  • Use appropriate statistical tests based on data distribution

  • Consider power analysis to determine adequate sample size

  • Apply corrections for multiple comparisons

  • Report effect sizes along with p-values

For disease model comparisons, age/sex-matched controls and standardized isolation/preparation protocols are essential to minimize technical variability.

How can I effectively use ADIPOR1 antibodies in co-localization studies with other metabolic markers?

For effective co-localization studies involving ADIPOR1:

• Antibody selection for multiplexing:

  • Choose ADIPOR1 antibodies from different host species than other target antibodies

  • Ensure non-overlapping fluorophore emission spectra

  • Validate each antibody individually before multiplexing

• Sequential immunostaining protocol:

  • Start with the least sensitive antigen

  • Consider tyramide signal amplification for weakly expressed proteins

  • Use complete washing between antibody incubations

  • Test for cross-reactivity between secondary antibodies

• Recommended co-localization markers:

  • Adiponectin (AdipoQ) - ADIPOR1's natural ligand

  • AMPK - downstream signaling partner

  • Glucose transporters (GLUT4) - functional pathway connection

  • Peroxisome proliferator-activated receptors (PPARs) - related metabolic regulators

• Quantitative co-localization analysis:

  • Calculate Pearson's correlation coefficient

  • Determine Manders' overlap coefficients

  • Use object-based analysis for discrete structures

  • Employ specialized software (JACoP in ImageJ, Imaris, etc.)

• Advanced microscopy techniques:

  • Confocal microscopy with appropriate z-stack sampling

  • Super-resolution approaches for membrane protein distribution

  • FRET analysis for protein-protein interaction confirmation

  • Live-cell imaging for dynamic interaction studies

Proper controls should include single-stained samples for each antibody to establish bleed-through parameters and unstained samples to set background thresholds.

How can ADIPOR1 antibodies be utilized in studying its interaction with adiponectin and downstream signaling pathways?

ADIPOR1 antibodies can be powerful tools for investigating receptor-ligand interactions and signaling cascades:

• Co-immunoprecipitation (Co-IP) approaches:

  • Use ADIPOR1 antibodies to pull down receptor complexes

  • Probe for adiponectin and signaling partners (AMPK, APPL1)

  • Consider crosslinking before lysis to stabilize transient interactions

  • Use appropriate lysis buffers containing mild detergents (0.5-1% NP-40 or CHAPS) to preserve membrane protein interactions

• Proximity ligation assay (PLA):

  • Combine ADIPOR1 antibodies with antibodies against adiponectin or downstream effectors

  • Visualize and quantify protein-protein interactions in situ

  • Provides spatial resolution of interaction events within cells

• Phospho-specific Western blotting:

  • Following adiponectin stimulation, monitor phosphorylation of:

    • AMPK (Thr172) - primary ADIPOR1 downstream target

    • p38 MAPK - secondary signaling pathway

    • ACC (Acetyl-CoA Carboxylase) - metabolic effector

  • Compare phosphorylation kinetics in control vs. ADIPOR1-depleted cells

• ChIP-seq approaches:

  • Use ADIPOR1 pathway stimulation followed by ChIP-seq for transcription factors

  • Identify genes regulated by ADIPOR1 signaling

  • Combine with RNA-seq for comprehensive pathway analysis

• CRISPR-Cas9 modification strategies:

  • Generate epitope-tagged ADIPOR1 variants

  • Create specific domain mutations to assess signaling outcomes

  • Validate with antibody detection in various assays

The full signaling cascade analysis should incorporate time-course experiments and dose-response studies to capture the dynamics of ADIPOR1-mediated signaling.

What are the considerations for using ADIPOR1 antibodies in flow cytometry for analyzing expression in different cell populations?

Flow cytometric analysis of ADIPOR1 requires specific technical considerations:

• Cell preparation optimization:

  • Gentle cell dissociation methods to preserve membrane proteins

  • Avoid harsh proteolytic enzymes that might cleave surface ADIPOR1

  • Use short fixation times (10-15 minutes) with 2-4% paraformaldehyde

• Permeabilization strategies:

  • ADIPOR1 is a multipass membrane protein with both internal and external epitopes

  • Test different permeabilization agents (saponin, Triton X-100, methanol)

  • Optimize concentration and time for each cell type

• Antibody validation for flow cytometry:

  • Confirm specificity using positive controls (ADIPOR1-transfected cells)

  • Include negative controls (non-transfected cells or irrelevant transfectants)

  • Use appropriate isotype controls to set gating boundaries

• Staining protocol recommendations:

  • Titrate antibody concentration (start with 1:50-1:100)

  • Extend incubation times (45-60 minutes) at 4°C

  • Include blocking step with serum from secondary antibody species

• Multiparameter analysis design:

  • Combine with markers of adipose tissue macrophages (CD11c, CD206)

  • Include adipocyte markers (FABP4, Perilipin)

  • Add metabolic activity indicators (Mitotracker, glucose uptake probes)

• Data analysis approaches:

  • Report median fluorescence intensity rather than percent positive

  • Use fluorescence minus one (FMO) controls for accurate gating

  • Consider visualization tools like tSNE or UMAP for high-dimensional analysis

For studies of tissue-derived cells, fresh isolation and immediate analysis are preferred, as cryopreservation may affect membrane protein detection.

How can ADIPOR1 antibodies be used to investigate the relationship between receptor expression and obesity/insulin resistance?

Investigating ADIPOR1's role in obesity and insulin resistance requires multifaceted approaches:

• Tissue-specific expression analysis:

  • Compare ADIPOR1 levels in adipose depots (subcutaneous vs. visceral)

  • Analyze expression in muscle, liver, and pancreatic tissues

  • Correlate with BMI, insulin sensitivity indices, and adiposity measures

  • Use laser capture microdissection with IHC to analyze specific regions

• Intervention study designs:

  • Monitor ADIPOR1 expression before and after weight loss

  • Track changes during exercise interventions

  • Assess alterations with dietary modifications

  • Correlate with improvements in insulin sensitivity

• Cell subtype analysis in adipose tissue:

  • Use flow cytometry with ADIPOR1 antibodies to analyze:

    • Mature adipocytes vs. stromal vascular fraction

    • M1 vs. M2 macrophage populations

    • Preadipocytes at different differentiation stages

  • Correlate cellular distribution with metabolic parameters

• Functional assays incorporating ADIPOR1 detection:

  • Glucose uptake assays with ADIPOR1 immunostaining

  • Fatty acid oxidation measurements with ADIPOR1 quantification

  • Insulin signaling pathway analysis with ADIPOR1 co-staining

• Translational research approaches:

  • Develop tissue microarrays from patient cohorts

  • Quantify ADIPOR1 immunostaining intensity

  • Correlate with clinical parameters and treatment outcomes

  • Consider genetic variants (SNPs) that might affect antibody binding

When designing these studies, controlling for confounding factors (age, sex, medications, comorbidities) is essential for meaningful correlations between ADIPOR1 expression and metabolic parameters.

How might ADIPOR1 antibodies contribute to research on therapeutic targeting of the adiponectin pathway?

ADIPOR1 antibodies can facilitate therapeutic development in several ways:

• Target validation studies:

  • Use antibodies to confirm ADIPOR1 expression in disease-relevant tissues

  • Correlate expression levels with disease severity and progression

  • Identify patient subpopulations with altered ADIPOR1 expression patterns

• High-throughput screening support:

  • Develop ELISA-based binding assays using anti-ADIPOR1 antibodies

  • Create cell-based assays combining ADIPOR1 antibodies with functional readouts

  • Use antibodies to validate hits from computational drug design

• Mechanism of action studies:

  • Monitor ADIPOR1 conformational changes upon compound binding

  • Track receptor internalization or clustering after drug treatment

  • Assess alterations in protein-protein interactions using co-IP with ADIPOR1 antibodies

• Pharmacodynamic biomarker development:

  • Quantify ADIPOR1 expression changes as response markers

  • Monitor downstream signaling alterations (phospho-AMPK, etc.)

  • Develop immunohistochemical protocols for clinical sample analysis

• Therapeutic antibody development considerations:

  • Epitope mapping of existing antibodies to identify functional regions

  • Assessment of agonistic/antagonistic effects of current antibodies

  • Humanization strategies for therapeutic candidates

Researchers should consider developing antibodies against specific conformational states of ADIPOR1 and investigating bispecific antibodies that could modulate both ADIPOR1 and its signaling partners simultaneously.

What are the emerging techniques for studying ADIPOR1 that may require specialized antibodies?

Several cutting-edge techniques offer new avenues for ADIPOR1 research:

• Mass cytometry (CyTOF):

  • Requires metal-conjugated antibodies against ADIPOR1

  • Allows simultaneous assessment of 40+ markers

  • Enables comprehensive immune and metabolic profiling

  • Development of panel-specific ADIPOR1 antibodies needed

• Super-resolution microscopy applications:

  • Structured illumination microscopy (SIM)

  • Stochastic optical reconstruction microscopy (STORM)

  • Stimulated emission depletion (STED) microscopy

  • Each requires bright, photostable fluorophore conjugation to ADIPOR1 antibodies

• In vivo imaging approaches:

  • Near-infrared fluorophore-conjugated antibodies

  • Radiolabeled antibody fragments for PET imaging

  • Site-specific conjugation methods to maintain binding efficiency

• Single-cell proteomics integration:

  • Antibody-based techniques for detecting ADIPOR1 in single cells

  • Compatible fixation and permeabilization protocols

  • Multiplexed antibody panels including ADIPOR1

• Spatially resolved transcriptomics with protein detection:

  • Combined RNA-seq with antibody detection

  • Methods like MERFISH with immunofluorescence

  • Requires highly specific antibodies with minimal cross-reactivity

• Antibody engineering for optogenetic applications:

  • Light-activatable antibody fragments against ADIPOR1

  • Photocontrollable binding for temporal studies

  • Requires specialized modification of existing antibodies

These emerging techniques will require development of application-specific antibodies with particular properties tailored to each method's technical requirements.